Harnessing the potential of the PAM (PI3K/AKT/mTOR) pathway to improve outcomes for those affected by cancer.
Celcuity is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumor indications. Our lead product candidate, gedatolisib, is a highly differentiated, potential first-in-class, pan-PI3K, mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. PAM is one of the most important, and difficult to blockade, pathways involved in cancer.
Our Pipeline
Advancing a robust pipeline of targeted therapies with a focus on the PI3K/AKT/mTOR pathway – Celcuity has the potential to make a transformative difference in the treatment of breast and prostate cancers.
Our Lead Candidate
Gedatolisib potently inhibits all four Class I PI3K isoforms as well as mTORC1 and mTORC2 at low nanomolar (nM) concentrations to induce comprehensive inhibition of the PAM pathway.
Our Culture
Learn more about our mission-driven company, united by a shared commitment to bring hope to cancer patients who need it most.